A milestone for ATMP development in Sweden: official inauguration of new ATMP infrastructures at Lund University and Skåne University Hospital

On 9 April, a major step forward was taken in Sweden’s capacity to develop and deliver advanced therapies, with the official inauguration of Lund University’s pre-GMP facility and Skåne University Hospital’s ATMP Center. The inaugural event was held at Medicon Village, which brought together researchers, clinicians, life science companies, and decision-makers to discuss the history, progress, and future developments within the field of advanced therapy medicinal products (ATMP).

These newly launched facilities form a joint research and development environment that plays a critical role in bridging the gap between academic research and clinical application. Together, they offer the essential infrastructure to facilitate the translation of ATMP research into patient treatments.

The pre-GMP facility at Lund University will offer expertise, advanced equipment and process optimisation to facilitate the transition from early development to GMP-compliant manufacturing. The ATMP Center at Skåne University Hospital will in turn act as an entry point for ATMP-related clinical trials, as well as enabling the preparation and handling of ATMPs in a hospital setting, to facilitate the uptake of such therapies in patient care.

“This is a key investment in making Sweden and the Skåne region a frontrunner in ATMP development,” said Sarah Lidé, Deputy CEO at Medicon Village Innovation, who also provided closing remarks at the inaugural event.

To find out more about the newly inaugurated facilities:

https://www.stemcellcenter.lu.se/article/now-lunds-atmp-infrastructures-are-officially-open

Pictured, from left to right: Sarah Lidé, Medicon Village Innovation; Gisela Helenius, ATMP-centrum Region Skåne; and Anna Falk, LU ATMP Centrum.